Clinical Trials

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT02359968 2026-03-18

PROTECT

106 enrolled

Phase 3 Not yet recruiting

Esophageal Neoplasms

NCT07472868 2026-03-16

MEND-IT II

394 enrolled

Pathologic Complete Response

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Phase EARLY_PHASE1 Active not recruiting

2 enrolled

Colonic Neoplasms

NCT06269978 2026-03-10

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer

Phase 1 Recruiting

24 enrolled

Colorectal Neoplasms

NCT05491512 2026-03-09

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

121 enrolled

Oropharyngeal Neoplasms

NCT02047474 2026-03-06

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

46 enrolled 15 charts

Pancreatic Neoplasms

NCT04380545 2026-03-06

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Phase 1/2 Recruiting

15 enrolled

Carcinoma, Hepatocellular

NCT07070466 2026-03-06

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

40 enrolled

Phase 2 Active not recruiting

Esophageal Neoplasms, Stomach Neoplasms

NCT00707473 2026-03-05

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

31 enrolled

Sinonasal undifferentiated carcinoma, Paranasal Sinus Neoplasms

NCT04230187 2026-03-05

TRIBE-C

528 enrolled

Phase 1 Active not recruiting

Colorectal Neoplasms

NCT04522336 2026-03-05

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

16 enrolled

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

NCT04683315 2026-03-05

PANCREAS

84 enrolled

Pancreatic Neoplasms

NCT05677490 2026-03-04

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

382 enrolled

Phase 3 Active not recruiting

Adenocarcinoma Of Esophagus

NCT04094688 2026-03-03

SOLARIS

455 enrolled 13 charts

Colorectal Adenocarcinoma

NCT04215731 2026-03-03

FOBEAR

582 enrolled

Phase 4 Not yet recruiting

Rectal Neoplasms

NCT07446465 2026-03-03

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

42 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07026474 2026-03-02

RePaIr-HN

214 enrolled

Phase 2 Enrolling by invitation

Squamous Cell Carcinoma of Head and Neck

NCT07441369 2026-03-02

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

16 enrolled

Liver Metastases From Colorectal Cancer (mCRC)

NCT07176182 2026-02-27

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

236 enrolled

Phase 2/3 Not yet recruiting

Rectal Neoplasms

NCT07437287 2026-02-27

CROCOBIL

160 enrolled

Biliary Tract Neoplasms

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

30 enrolled

Cholangiocarcinoma

NCT05567835 2026-02-23

TOGAR

Phase 2 Terminated

3 enrolled

Stomach Neoplasms

NCT07419464 2026-02-19

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

46 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases

NCT02021422 2026-02-18

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Phase 1 Completed

13 enrolled

Pancreatic Neoplasms

NCT07418866 2026-02-18

FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer

70 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05413811 2026-02-17

ACT2

Phase NA Completed

180 enrolled

Gynecologic

Acquired Immunodeficiency Syndrome, Uterine Cervical Neoplasms

NCT06835387 2026-02-17

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

36 enrolled

Small Bowel Adenocarcinoma

NCT03388190 2026-02-13

METIMMOX

80 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03785873 2026-02-13

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Completed

34 enrolled 13 charts

Biliary Tract Neoplasms

NCT06501989 2026-02-11

Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer

Phase 2 Withdrawn

Colorectal Neoplasms

NCT06557889 2026-02-11

REDUCE

86 enrolled

Phase 3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04340141 2026-02-10

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

358 enrolled

Phase 1 Not yet recruiting

Pancreatic Neoplasms

NCT07401277 2026-02-10

Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum

32 enrolled

Dermatologic

Keratosis, Actinic

NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

36 enrolled

Phase EARLY_PHASE1 Terminated

Stomach Neoplasms

NCT02724202 2026-02-06

Curcumin in Combination With 5FU for Colon Cancer

15 enrolled

Colonic Neoplasms

NCT05412082 2026-02-06

SMART TNT

Phase 1 Recruiting

25 enrolled

Locally Advanced Rectal Cancer

NCT07214298 2026-02-06

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

35 enrolled

Pancreatic Neoplasms

NCT00556413 2026-02-05

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

42 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05062889 2026-02-03

ERASE-CRC

Phase 2 Suspended

477 enrolled

Colonic Neoplasms

NCT05838391 2026-02-03

Adaptive Radiation in Anal Cancer

Phase NA Recruiting

20 enrolled

Anus Neoplasms

NCT04495088 2026-02-02

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

550 enrolled

Rectal Neoplasms

NCT06958328 2026-02-02

LAP100

356 enrolled

Pancreatic Neoplasms

NCT07097142 2026-02-02

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

25 enrolled

Pancreatic Neoplasms

NCT06123338 2026-01-29

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

49 enrolled

Esophageal Neoplasms

NCT06739252 2026-01-28

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

Phase 2 Terminated

1 enrolled

Phase 2 Active not recruiting

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma, Klatskin Tumor

NCT04005339 2026-01-26

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

48 enrolled

Phase 1 Not yet recruiting

Biliary Tract Neoplasms, Gastrointestinal Neoplasms

NCT07363408 2026-01-23

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

30 enrolled

Colorectal Neoplasms

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

36 enrolled